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Abstract
Background: Circulating autoantibodies occur more frequently in cancer patients than in patients without cancer.
Methods and Findings: We examined sera from patients referred for pelvic mass symptoms to a tertiary university clinic. A
total of 127 were diagnosed with epithelial ovarian cancer while 386 had a benign condition. A screen for IgG anti-nuclear
antibodies (ANA) by indirect immunofluorescence on HEp-2 cells confirmed a highly significant overrepresentation of ANA
in the cancer group where 40% had detectable (i.e., a titer $160) ANA compared with less than 12% in the benign group.
The overrepresentation of ANA in the cancer group persisted (p,0.0001) after matching the age-profile of the benign group
with the ovarian cancer group. Only 19 out of 127 patients in the age-matched benign subgroup were positive for ANA
corresponding to an 85% specificity at 40% sensitivity of ANA as the only marker for malignancy. No correlation of ANA
positivity in either group with specific bands in immunoblots could be demonstrated even though immunoblot positivity
was clearly increased in the malignant group (41% vs. 3%). The presence, strength, and type of ANA did not correlate with
serum CA-125 values or with staging, and ANA outcome did not contribute with independent diagnostic information.
However, survival was significantly shorter in ANA-positive compared with ANA-negative cancer patients and patients with
CA-125 below the median CA-125 value in the cancer group had a significantly decreased survival when positive for ANA.
ANA status made no difference in the group with CA-125 values above the median. Also, there was a significant correlation
between speckled ANA-strength and histological tumor grade.
Conclusions: Circulating antibodies are a promising source for new biomarkers in cancer. Characterization of epitope
specificities and measurements of consecutive samples will be important for further elucidating the role of ANA in
evaluating ovarian cancer patients.
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Introduction
The immune system reacts to malignant tumor development by
developing circulating antibodies against tumor proteins and
specifically, since the body is tolerant to the normal proteins
expressed in the body, by developing antibodies against cancer-
associated post-translational modifications of these proteins as
shown e.g. in ovarian cancer [1]. A rapid and amplified
development of exquisitely discriminatory antibodies is a hallmark
of the human immune system e.g. in infections and reactions
against incompatible tissues in transplantation and transfusion.
Despite the promises of arrays of recombinantly expressed proteins
for detecting the reactivity patterns of cancer-specific antibody
responses [2], studies using proteins purified from relevant tumor
cell lines as antigens in screening for cancer specific antibodies
show remarkably better results, i.e., stronger reactivity and
improved specificity [1]. When an immune response has evolved
against a pathological cancer-associated epitope the reactivity may
spread (epitope-spreading) to include epitopes present on parts of
the normal protein structures because the proteins are being
processed as foreign objects through recognition of altered parts of
their structure. Such alterations may also be associated with
various other pathologies e.g. in inflammatory and infectious
conditions. This likely explains part of the reactivity of circulating
antibodies in cancer sera against unmodified/processed recombi-
nant antigens. The specific immunoreactivity against tumor
antigens dependent on cancer-specific protein modifications seems
a promising mechanism to exploit for developing more specific
laboratory tests for cancer. In this way the immune system is a
sensitive sensor of altered proteins in the body. The proteins
themselves may or may not reach the circulation, and, if present
only occur temporarily [3] and at very low concentrations and
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the immune response is quite stably reflected by the circulating
antibody population. The challenge in detecting the unique
cancer-associated antibodies then is to choose the appropriate
target antigens. The idea of using cancer cell line exosomes as
antigenic targets for such quantitative immunoassays is attractive
and has shown promising results in ovarian cancer studies as
mentioned above. The antigen preparation for such assays is,
however, complicated and difficult to standardize. Alternatively, it
may be possible to use cancer cell lines optimized for other
purposes as a tool to measure circulating antibody specificities
supporting a cancer diagnosis. It has previously been shown in
small studies that antinuclear antibodies (ANA) circulate more
frequently in a number of different malignancies [4]. In this study
we evaluate the HEp-2 cell line commonly used for screening for
ANA associated with rheumatic disease to test for the presence of
cancer-specific autoantibodies in sera from a large cohort of well-
characterized patients referred to a tertiary university clinic for
diagnostic work-up because of a pelvic mass. In total we examined
the IgG response against HEp-2 cells in 558 patients of which 173
had some type of malignant ovarian conditions and the remainder
had benign pelvic masses.
Materials and Methods
The Pelvic Mass Study
The Pelvic Mass study is a Danish prospective study of ovarian
cancer, covering biochemistry and molecular biology with the
purpose of identifying prognostic factors as well as factors that
differentiate benign and malignant conditions. Samples originate
from women referred to an outpatient clinical because of symptoms
of a pelvic mass. The study was performed according to the
Declaration of Helsinki including obtaining written informed
consent from all participating patients. The study has been approved
bythe TheDanishNationalCommitteeforResearchEthics,Capital
Region (approval codes KF01-227/03 and KF01-143/04).
Study Design
From September 2004 559 women admitted to the Gynecologic
Clinic, Rigshospitalet, Denmark for surgery because of a pelvic
mass, were enrolled. Of these patients 130 were diagnosed with
ovarian cancer (127 epitelial, 3 non-epitelial), 26 with a borderline
ovarian tumor, 386 with a benign disease, and 17 patients with non-
ovarian cancer. All consecutive patients $18 years of age with the
suspicion of a pelvic mass were informed both in writing and
verbally and were invited after written consent to participate in the
study. Patients were examined with an abdominal and vaginal
ultrasound and serumCA-125wasanalysed.Exclusioncriteriawere
pregnancy, previous cancer or borderline tumor, no understanding
of information or cancellation of planned surgery because of no
suspicion of pelvic disease after further examinations.
All tissue specimens obtained during the surgery were examined
by a pathologist specialized in gynecologic cancer. All patients are
registered in Danish Gynaecologic Cancer Database (DGCD),
which is a compulsory research and quality on-line database. The
FIGO stage distribution for the ovarian cancer were 18 stage I
patients, 12 stage II patients, 71 stage III patients and 26 stage IV
patients. A total of 99 patients had serous adenocarcinama, 7
patients mucinous adenocarcinoma and 21 patients had tumors of
other histological types.
For the borderline ovarian tumors the FIGO stage distribution
were: 23 stage I patients, 2 stage III patients and one patient with a
stage IV tumor. Of the 26 borderline ovarian tumors, 16 were
serous and 10 were mucinous (Table 1).
All ovarian cancer cases in this study were traced in the Danish
Central Population Register (CPR) and date of death or
emigration up to January 11th 2011, whichever came first, were
registered. In addition, information about treatment (surgery and
chemotherapy) and cause of death was established from the DGC
database. During the follow-up period, a total of 73 OC patients
had died from ovarian cancer (median follow-up time: 18 months,
range: 1–68) and 54 patients were still alive (median follow-up
time: 56 months, range: 38–75).
Sample Processing
Blood samples were secured less than 15 days before surgery. All
blood samples were collected and handled according to the
conclusions of a previous study [5]. Handling and treatment of the
blood samples were performed within one working day (i.e.,i nl e s s
than 6 h). Thus, blood samples were left to clot at room temperature,
and serum was isolated by centrifugation at 2000 g for 10 min. All
sera were stored at 280uC in aliquots until analyses were performed.
Laboratory Analyses
CA-125 values were determined in all sera by quantitative
immunoassay (Brahms CA125 II Kryptor, BRAHMS GmbH)
using $35 U/mL as a cut-off for positivity [6].
Table 1. Study demographics in patients diagnosed with
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Age (median/range) 66 (31–88) 55 (22–84) 45 (20–90)** ,0.0001
CA125 (U/mL)
(Median/range)
469 (6–12.310) 50 (12–853) 27 (2–1906) ,0.0001
*endometrioid adenocarcinoma N=11, Clear cell neoplasms N=6 and
carcinosarcoma N=4.
**No significant difference for the subset of 127 matched patients with benign
conditions: Median age: 64 (range 54–90).
doi:10.1371/journal.pone.0030997.t001
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mento, CA) was performed by indirect immunofluorescence
essentially as described [7]. HEp-2 originates from a human larynx
carcinoma that was grown in rats [8] and is routinely used to detect
and classify ANA that are characteristic for various autoimmune
systemic connective tissue diseases [9]. It represents a standardized
substrate for semiquantitative assessment of ANA reactivity (IgG
antibodies) by indirect immunofluorescence. In brief, sera were
diluted 1:160 in PBS (phosphate-buffered saline) and 15–20 ml were
applied to each well of the HEp-2 slides followed by incubation at
room temperature for 30 min. After 10 min washing in PBS 15–
20 ml fluorescein isothiocyanate (FITC)-labelled rabbit immuno-
globulins against human IgG (diluted 1:40 in PBS) were added and
incubation continued for another 30 min. Wells were again rinsed
for 10 min with PBS and the slides mounted in PBS with coverslips.
Results were visually scored as negative (score 0), borderline positive
(score 1), weakly positive (score 2), intermediate positive (score 3), or
strongly positive (score 4). Positive samples were furthermore
classified as cytoplasmic or nuclear and the latter was subdivided
into 8 different antinuclear staining patterns by visual inspection of
the fluorescence distribution.
Immunoblotting was performed using HeLa cell nuclear and
cytoplasmic antigens (TriChem, Copenhagen, Denmark) that were
separated by SDS-PAGE in 4–20% gels (InVitrogen, Copenhagen,
Denmark) and transferred to nitrocellulose membranes (Whatman,
Dassel, Germany). The membranes were blocked in TTN (50 mM
Tris, pH 7.5,1%Tween 20, 0.3 M NaCl)andindividuallaneswere
inclubated with sera diluted 1:100 in TTN for 1 h followed by 36
washing in TTN. The membranes were then incubated 1 h with
alkaline phosphatase-conjugated rabbit immunoglobulins agains
human IgG diluted 1:1000 in TTN. After 36 washing in TTN,
membranes were developed using BCIP/NBT substrate tablets
(Kem-En-Tek, Copenhagen, Denmark).
Data Handling
Unless otherwise noted only fluorescence scores of 2 and above
were considered positive. The proportions in contingency tables
were compared using Fisher’s exact test and diagnostic perfor-
mance was assessed using ROC curves. All graphical and
statistical operations were performed using the Prism v. 5.0
program (GraphPad Software, San Diego, CA). Survival curves
were estimated by the Kaplan-Meier method using log rank
(Mantel-Cox) for statistical analysis of significance. The impact of
IgG ANA (positive and negative) on mortality was estimated on
the basis of the Cox proportional hazard model [10], applying the
two-tiered scale using time since primary surgery as the time axis.
The assumption of proportionality for the Cox model was assessed
using Schoenfeld and martingale residuals as well as graphical
methods using SAS, version 9.1. The regression analyses were
adjusted for FIGO stage (I, II, III and IV), histological type of
tumor (serous, mucinous, endometroid and other histological
types), age at diagnosis (linear) and histological grade (high,
moderate and low). Confidence intervals (95% CI) for the
corresponding parameters in the multivariate COX regression
model are presented. The analyses were performed using the SPSS
11.5 Statistical Software and graphs are constructed in the Prism
program. Significance cut-off was p#0.05.
Results and Discussion
Increased incidence of AntiNuclear Antibodies (ANA) in
sera from patients with malignant pelvic masses
All sera (Table 1) were tested for the presence of circulating IgG
antibodies reacting with antigens in the HEp-2 cancer cell line
used for screening of antinuclear autoantibodies (ANA). We find
that circulating ANA are detected in patients with malignant
pelvic conditions with a statistically highly significantly (p,0.0001)
increased frequency compared with the controls, i.e., patients
suffering from benign pelvic conditions (Table 2). Patients with
borderline conditions (n=26) had ANA in 11% of the cases.
Overall, 40% (51/127) of the patients with epithelial ovarian
cancer were positive for antinuclear antibodies (Figure 1) com-
pared with 11% in the group composed of women diagnosed with
a benign ovarian tumor and with about 5% of the normal
background population [11].
There is no consensus [11] regarding the possibility that the
frequency of ANA increases with age but several publications have
suggested this to be the case [12,13]. Since the median age of the
group with benign conditions was significantly lower than the
median age of the ovarian cancer cases (cf. Table 1) we did the
analysis also in a subgroup of the benign cohort age-matched to
the 127 patients with epithelial ovarian cancer (Figure 1B). Even
though a slightly increased frequency of ANA was observed in the
age-matched benign group (13%) this was still highly significantly
lower (p,0.0001) than in the group with ovarian cancer. Thus in
our patient population ANA were found about 4 times as often in
ovarian cancer as in benign ovarian cases.
Correlation of ANA with survival and tumor stage
Overall, the presence of ANA was significantly correlated with
survival, since 48% of the patients (n=73) that died and only 28%
of the surviving patients (n=54) were positive for ANA (Figure 2A).
This difference was statistically significant (p=0.03). Conversely,
there was no correlation between the incidence of ANA-positivity
and tumor stage, i.e. the frequency of ANA in early (stage I–II)
versus in late stage (stage III–IV) epithelial cancer was not
statistically different. Also, no correlation were found between









membr. Homog. Speckled Cytopl.
Cancer n (%) (n=127) 51 (40.2%) 2 (1.5%) 10 (7.9%) 3 (2.3%) 1 (0.8%) 0 5 (3.8%) 23 (17.4%) 12 (9.1%)
Benign n (%) (n=386) 43 (11.2%) 1 (0.3%) 6 (1.6%) 0 2 (0.8%) 2 (0.8%) 13 (3.4%) 12 (3.1%) 9 (2.3%)
p-value ,0.0001 NS 0.0013 0.0164 NS NS NS ,0.0001 0.0017
Fisher’s exact test was used to obtain p-values. Some sera contain ANAs of more than one specificity. Centr., centromere; Nuclear membr., nuclear membrane; Homog.,
homogeneous; cytopl., cytoplasmic; NS, non significant.
doi:10.1371/journal.pone.0030997.t002
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pattern of ANA-staining.
Univariate Kaplan-Meier survival analysis was performed on all
ovarian epithelial cancer patients (n=127) and on FIGO stage III
patients (n=71) using the two-tiered scale (positive (all scores of 2
or above) or negative) cut-off for ANA (Figs. 2B & 2C). A
significant difference between the two groups of patients were
observed when all ovarian epithelial cancer patients were included
(p=0.023), whereas no significant difference were observed when
stratifying stage III ovarian cancer patients (p=0.124) (Fig. 2C).
In a multivariate Cox survival analysis of the 127 ovarian
epithelial cancer cases, independent prognostic factors were found
to be FIGO stage (P,0.0001: HR=2.023, 95% CI: 1.417–2.889)
and age at diagnosis (HR=1.042, 95% CI: 1.020–1.066). No
significant survival differences were seen among patients with the
different levels of ANA (positive vs. negative) (p=0.221), different
histological types (p=0.652) and histological grades (p=0.427).
The loss of significance in multivariate (Cox) analysis suggests that
ANA is not an independent variable but associated with other
known strong prognostic factors such as FIGO stage. Accordingly,
while the presence of ANA is clearly associated with survival in
univariate analysis of all samples (Fig. 2B) the significance is lost in
the stage-III subset of samples (Fig. 2C).
In the group of 127 patients with epithelial ovarian cancer most
(n=122) had CA-125 values above the cut-off (35 U/mL). Analysis of
survival in the two groups of patients with CA-125 values below or
above the median value of 469 U/mL (n=64 and 63, respectively)
showed, as expected, a highly significant (p,0.0001) decreased survival
in the high CA-125 group (data not shown). When adding ANA-status
the data show that for patients below the median CA-125 valule
(n=64, of which 5 were below the cut-off of 35 U/mL) there is a
statistically significant decreased survival if they are also positive for
ANA (n=24, p,0.015) (Fig. 2D). In patients with CA-125 values
above the median (n=63) there was no such difference in survival
between the ANA-positive (n=27) and ANA-negative (n=36) patients
(Fig. 2E).
Correlation of ANA intensity and ANA patterns with
malignancy and histological grade of tumor
Routinely, immunofluorescence intensity is scored as negative
or weakly, medium or strongly positive. Borderline positives were
scored as negative in this study. Examples of strongly positive
samples from patients with malignancies are shown in Figures 3A
and 3B. It was found that, except in three benign samples, only
samples from patients with ovarian cancer showed strongly
reacting ANA (Figure 3C). Also, most of the ANA-positive
samples belonged to one of four staining pattern groups:
homogeneous, speckled, nucleolar, or cytoplasmic except for some
strongly reacting samples with other patterns (mitotic spindle,
nuclear dots and centromere patterns) in the malignant group. As
seen by the numbers in Table 2 the speckled, nucleolar, and
cytoplasmic patterns were statistically highly significantly more
frequent in the samples from malignant cases while the incidence
(3–4%) of ANA with a homogeneous staining pattern was the same
in both groups and in fact is approaching the background
frequency of this ANA pattern in healthy controls. A correlation of
a speckled pattern with more aggressive disease was suggested by
analysis of the histological grade of tumor. For the 127 samples
from the group with epithelial carcinomas the histological grade was
available from 122 while histological grade could not be typed in 5
cases (4 carcinosarcoma and one ovarian cancer case diagnosed by
presence of cancer cells in the ascites fluid). Highly differentiated
cancers were represented by 17 sera while moderately (n=55) and
poorly (n=50) differentiated cancers represented the remaining
samples in this group. We found that while ANA positivity occurred
withthe same frequency in the two groups (41% and 44% (high and
low differentiation grade, respectively)) speckled patterns were
practically absent (only one sample had a borderline positive
pattern) in the highly differentiated group (Figure 4). This difference
was statistically significant (p=0.04).
No predominant immunoblotting pattern
All available sera (375/385 benign and 167/179 malignant)
were examined for IgG reactivity with specific protein bands on
blots of SDS-PAGE separated HeLa-cell extracts. No predomi-
nant antigen specificity appeared and both unknown bands and a
variety of bands with molecular weight characteristics of known
antigens were observed (data not shown). A total of 41% of the
epithelial cancer ANA-positive samples available for immunoblot
analysis (18/44 available out of 51 ANA-positive) revealed bands
(representing 7–8 different specificities) while only one out of the
available ANA-negative malignant samples (74 available out of 76)
was positive. For the entire benign group, a total of 11 samples
(3%) (5 of which were ANA-positive) out of 375 (40 ANA-positive
Figure 1. Proportion of positive results from the Antinuclear
Antibodies (ANA)-screening of benign vs. malignant samples,
Overall 40% of the patients with malignancies were positive
for one or more ANA specificity (cf. also Table 2). This is a highly
significantly fraction when compared to the patients with benign
condition, both in the complete data set (A) and when comparing
between age-matched groups (B).
doi:10.1371/journal.pone.0030997.g001
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immunoblotting and showed 4–5 different antigenic specificities.
Performance of CA-125 as a diagnostic tool for ovarian
malignancy with or without added ANA data
Apart from the prognostic information suggested by the
significant findings in the survival curve analyses discussed above
the presence of ANA did not appear to contribute overall with
diagnostic information independently of serum CA-125. Using
35 U/mL CA-125 as the cut-off a sensitivity of 95% at 60%
specificity was obtained from a ROC curve with an AUC of 0.93
for differentiating the benign from the group of patients with
epithelial ovarian cancer (data not shown). Almost all the ANA-
positive samples from malignant cases had serum CA-125 values
above the cut-off (Fig. 5). Thus, including ANA-positivity as a
parameter for the diagnosis of ovarian cancer only added one
malignant sample which had a CA-125 value below 35 U/mL,
while in the benign age-matched group we found 12 ANA-positive
Figure 2. Mortality and presence of Antinuclear Antibodies (ANA). In (A) is shown the frequency of detection of ANA in the group of patients
with epithelial ovarian cancer (n=127) depending on their survival status (alive or dead). There is a statistically significant (p=0.03) increase in the
frequency of ANA in the group where the patients are dead. In (B–D) Kaplan-Meier survival curves are depicted. The graph in (B) indicates the survival
of the 127 patients of whom 76 were negative for IgG ANA and 51 were positive. In (C) survival data grouped according to ANA status for the 71
patients with FIGO stage III cancer are shown. (D) shows survival of patients with CA-125 values below the median (469 U/mL) stratified according to
ANA-status while (E) shows the same data for patients with CA-125 values above the median. NS, non-significant. Upward lines indicate instances of
censored patients.
doi:10.1371/journal.pone.0030997.g002
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group above 35 U/mL. Thus, for the age-matched sample set a
serum that is double-positive (positive for ANA and a CA-125
value above cut-off) (n=57) is 7 times more likely (7/254 vs. 50/
254) to belong to the group of malignant samples, i.e., 39% of the
samples (50/127) from the malignant group and 6% (7/127) from
the benign group are double-positive.
Figure 3. Antinuclear Antibodies (ANA) specificities. Examples of ANA-patterns of strongly positive sera staining in a cytoplasmic (A) and a
speckled (B) pattern. In (C) is shown the distribution of the main types of ANA patterns as well as the signal strength in the benign and the malignant
group. Strongly positive samples are almost only seen in the group with malignancy.
doi:10.1371/journal.pone.0030997.g003
Figure 4. Relationship between ANA-staining intensity and
histological grade of tumor (high, moderate, and poorly
differentiated). While grading had no significant relationship with
ANA-positivity of any specificity the presence of a speckled ANA pattern
was significantly correlated with moderate-poor differentiation grade
when compared with highly differentiated tumors (p=0.04).
doi:10.1371/journal.pone.0030997.g004
Figure 5. No correlation between serum-CA-125 values and the
presence and intensity of ANA. The immunofluorescence score is
depicted as a function of CA-125 values for the samples from benign
(red symbols) and malignant cases (green symbols). Cut-off for
positivity in the CA-125 test is 35 U/mL. All patients with benign
ovarian tumors and epithelial ovarian cancers are included in this figure.
doi:10.1371/journal.pone.0030997.g005
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The search for novel circulating biomarkers in ovarian cancer is
intense and has harnessed a number of methods including
proteomic analyses of the repertoire of circulating proteins and
peptides [14]. However, despite much efforts no new biomarkers
have yet emerged as an alternative to the established but imperfect
CA-125 marker [6,15]. Earlier work has shown that cancer-
specific antigens may be released to the circulation in very low and
transient concentrations. By virtue of being altered self-molecules,
however, such antigens are likely to provoke an immune response.
Accordingly, a number of studies have shown anti-cancer
antibodies circulating in a wide variety of types of cancer patients
[16]. In ovarian cancer this includes some recent studies where the
immunoreactivity with specific proteins derived from cancer cell
exosomes or cancer cell lines were clearly and specifically
increased [1] for a number of antigen targets [17]. A more
convenient way of testing for the presence of antigens present in
cancer cells might be to use standardized cellular substrates from
cultured cancer cells as in the present study.
Here, the disease sensitivity based on a positive ANA-result was
41% and while this is not a diagnostically useful sensitivity the
numbers indicate that a positive ANA-screening is quite specific
for malignancy in this group of patients, i.e., only 42 out of 385
patients in the benign group had a positive result, corresponding to
a specificity of about 89% in the group diagnosed with ovarian
cancer. Using ANA as the only marker we got a comparable 85%
specificity at 40% sensitivity in the age-matched samples sets.
Moreover, in the group of patients with malignant disease the
presence of ANA correlated with a worse prognosis. Notably, a
homogeneous ANA was as frequent in the benign group as the
malignant group while a speckled ANA-pattern specifically
correlated with moderately to poorly differentiated tumors. There
was no indication of a common protein specificity of these
antibodies when tested on proteins extracted from HeLa cells.
Overall, the results of this study suggest that the demonstration
of antinuclear antibodies may have some value as a prognostic
biomarker in patients with epithelial ovarian cancer. In cases with
CA-125 above cut-off but below the median value the presence of
ANA indicated a subgroup of patients that had worse survival.
This association was not observed, however, in the group of highly
increased CA-125 values. These data indicate that the use of ANA
may be focused on patients with intermediately increased CA-125
values but firm conclusions depend on further investigations in
larger groups of patients. The data do not allow any conclusions to
be drawn regarding changes in ANA levels during treatment. This
will rely on studies with consecutive samples.
The mechanisms behind the association of ANA with worse
prognosis are not clear but the magnitude of an immune response
depends on the antigenic stimulus. Thus, for faster growing or
larger tumors it would be expected that more immunogenic
material stimulates the immune system. A future characterization
of epitope specificities is an important part of elucidating the
importance of antibodies with ANA specificities in the evaluation
of ovarian cancer patients.
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